In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Pliant Therapeutics Inc (NASDAQ: PLRX) closed at $11.88 down -0.17% from its previous closing price of $11.90. In other words, the price has decreased by -$0.17 from its previous closing price. On the day, 0.61 million shares were traded. PLRX stock price reached its highest trading level at $11.9 during the session, while it also had its lowest trading level at $11.21.
Ratios:
For a deeper understanding of Pliant Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.72 and its Current Ratio is at 17.72. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on December 08, 2023, initiated with a Overweight rating and assigned the stock a target price of $41.
On May 18, 2023, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $48.
On April 13, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $44.Robert W. Baird initiated its Outperform rating on April 13, 2023, with a $44 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 17 ’24 when Coulie Bernard sold 25,721 shares for $17.23 per share. The transaction valued at 443,173 led to the insider holds 316,382 shares of the business.
Lefebvre Eric sold 10,295 shares of PLRX for $177,383 on Jan 17 ’24. The Chief Medical Officer now owns 156,920 shares after completing the transaction at $17.23 per share. On Jan 17 ’24, another insider, Hull Hans, who serves as the Chief Business Officer of the company, sold 9,786 shares for $17.23 each. As a result, the insider received 168,613 and left with 185,069 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PLRX now has a Market Capitalization of 717793152 and an Enterprise Value of 232768416. For the stock, the TTM Price-to-Sale (P/S) ratio is 452.94 while its Price-to-Book (P/B) ratio in mrq is 1.50. Its current Enterprise Value per Revenue stands at 147.322 whereas that against EBITDA is -1.277.
Stock Price History:
Over the past 52 weeks, PLRX has reached a high of $30.85, while it has fallen to a 52-week low of $11.73. The 50-Day Moving Average of the stock is -20.33%, while the 200-Day Moving Average is calculated to be -26.03%.
Shares Statistics:
For the past three months, PLRX has traded an average of 362.98K shares per day and 327440 over the past ten days. A total of 59.92M shares are outstanding, with a floating share count of 52.74M. Insiders hold about 12.44% of the company’s shares, while institutions hold 95.70% stake in the company. Shares short for PLRX as of 1713139200 were 7620895 with a Short Ratio of 21.00, compared to 1710460800 on 7002349. Therefore, it implies a Short% of Shares Outstanding of 7620895 and a Short% of Float of 12.879999999999999.
